Tuberculosis vaccine - Antigenics
Latest Information Update: 24 Oct 2021
At a glance
- Originator Antigenics
- Developer Antigenics; Brigham and Womens Hospital
- Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Tuberculosis in USA (Injection)
- 27 Aug 2001 Aquila Biopharmaceuticals has been integrated into Antigenics
- 01 Dec 2000 Aquila Biopharmaceuticals has been acquired by Antigenics